News | January 12, 2026
Evotec subsidiary bags Gates Foundation grant to expand global access to biologics
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The grant will fund ten new J.MD projects over the next three years, targeting multiple global health threats
The clearance marks a major step in Diabeloop’s ambition to become a central partner for insulin pump manufacturers and expand access to automated insulin delivery in the US market
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Supports production of AbbVie's current and next-generation immunology and neuroscience medicines
New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US
Nxera will take full responsibility for regulatory approvals, clinical development where required, manufacturing and commercialization in the licensed territories
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The agreement, signed in December 2025, grants Takeda an exclusive worldwide license to use Halozyme’s proprietary recombinant human hyaluronidase PH20 enzyme (rHuPH20) with vedolizumab
Subscribe To Our Newsletter & Stay Updated
